Clinical use of microRNAs as potential non-invasive biomarkers for detecting non-small cell lung cancer: A meta-analysis

被引:46
|
作者
Wang, Huoqiang [1 ]
Wu, Songnian [2 ]
Zhao, Long [1 ]
Zhao, Juan [1 ]
Liu, Jinjun [1 ]
Wang, Zhihao [1 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Nucl Med, Shanghai 200433, Peoples R China
[2] Shanghai GMS Pharmaceut Co Ltd, Dept Prod Technol, Shanghai, Peoples R China
关键词
diagnostic; non-small cell lung cancer; meta-analysis; microRNA; DIAGNOSTIC-VALUE; DIGITAL PCR; EXPRESSION; PLASMA; SPUTUM; BLOOD; SERUM; MIRNAS; QUANTIFICATION; ADENOCARCINOMA;
D O I
10.1111/resp.12444
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Emerging studies have revealed that microRNA (miRNA) in body fluid may serve as a potential biomarker to detect non-small cell lung cancer (NSCLC). However, the diagnostic accuracy of miRNA for NSCLC detection is still under debate because there is inconsistency in previous studies. Hence, we conducted this meta-analysis to comprehensively evaluate the diagnostic performance of miRNA. A systematic literature search was performed to retrieve relevant articles in PubMed and other databases, and STATA 12.0 (StataCorp, College Station, TX, USA) was used to calculate the pooled parameters. A total of 28 articles involving 2121 NSCLC patients and 1582 healthy controls were included in this meta-analysis. The overall pooled sensitivity and specificity of miRNA were 0.75 and 0.79, respectively. The pooled positive likelihood ratio was 3.6, negative likelihood ratio was 0.32 and diagnostic odds ratio was 12. The area under the curve (AUC) was 0.84. Subgroup and meta-regression analyses established that miRNA assays were more accurate in Caucasian populations (AUC of 0.86, sensitivity of 0.79 and specificity of 0.82, respectively) than in Asian populations (AUC, sensitivity and specificity of 0.83, 0.72 and 0.80, respectively). In addition, the multiple miRNA assays (AUC of 0.89, sensitivity of 0.83 and specificity of 0.82, respectively) showed a higher accuracy than single miRNA assays (AUC, sensitivity and specificity of 0.81, 0.77 and 0.71, respectively) in NSCLC detection. Subgroup analyses based on specimen types suggested that blood-based miRNA (AUC of 0.86, sensitivity of 0.78 and specificity of 0.80, respectively) may have a higher diagnostic accuracy as biomarkers than sputum-based miRNA (AUC of 0.81, sensitivity of 0.69 and specificity of 0.80, respectively). In conclusion, miRNA may serve as a potential biomarker in NSCLS detection, especially the multiple miRNA from blood, with a relatively high diagnostic accuracy.
引用
收藏
页码:56 / 65
页数:10
相关论文
共 50 条
  • [41] Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges
    Velcheti, Vamsidhar
    Pennell, Nathan A.
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (18)
  • [42] Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer
    Dejima, Hitoshi
    Iinuma, Hisae
    Kanaoka, Rie
    Matsutani, Noriyuki
    Kawamura, Masafumi
    ONCOLOGY LETTERS, 2017, 13 (03) : 1256 - 1263
  • [43] Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer
    Louisa Stern
    Erik Mueller
    Eugen Bellon
    Matthias Reeh
    Rainer Grotelueschen
    Cenap Guengoer
    Nathaniel Melling
    Mara Goetz
    Daniel R. Perez
    Jakob R. Izbicki
    Tamina Rawnaq-Möllers
    Tarik Ghadban
    Scientific Reports, 11
  • [44] Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer
    van der Drift, Miep A.
    Hol, Bernard E. A.
    Klaassen, Corne H. W.
    Prinsen, Clemens F. M.
    van Aarssen, Yvonne A. W. G.
    Donders, Rogier
    van der Stappen, Jos W. J.
    Dekhuijzen, P. N. Richard
    van der Heijden, Henricus F. M.
    Thunnissen, Frederik B. J. M.
    LUNG CANCER, 2010, 68 (02) : 283 - 287
  • [45] Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer
    Stern, Louisa
    Mueller, Erik
    Bellon, Eugen
    Reeh, Matthias
    Grotelueschen, Rainer
    Guengoer, Cenap
    Melling, Nathaniel
    Goetz, Mara
    Perez, Daniel R.
    Izbicki, Jakob R.
    Rawnaq-Moellers, Tamina
    Ghadban, Tarik
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [46] A meta-analysis of minimally invasive surgery versus thoracotomy for centrally located non-small cell lung cancer
    Li, Zhengjun
    Xia, Mozhu
    Liu, Chang
    Wang, Tao
    Ren, Yi
    Liu, Yongyu
    JOURNAL OF THORACIC DISEASE, 2021, 13 (01) : 252 - 261
  • [47] The clinical and prognostic impact of aldehyde dehydrogenase 1 in non-small cell lung cancer: a meta-analysis
    Xue, Jinru
    Zhao, Yan
    Zou, Qingxu
    Liang, Feihai
    Lin, Fengwu
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (03) : 1914 - +
  • [48] The Clinical Efficacy and Safety of Paclitaxel Liposome on the Patients with Non-Small Cell Lung Cancer: A Meta-Analysis
    Hu, Xingsheng
    Lin, Lin
    Xing, Puyuan
    Zhang, Changgong
    Wang, Lin
    Liz, Yiqun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S902 - S902
  • [49] EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: A meta-analysis
    Zhang, Qiong
    Dai, Hong-Hai
    Dong, Hong-Yun
    Sun, Cheng-Tao
    Yang, Zhe
    Han, Jun-Qing
    LUNG CANCER, 2014, 85 (03) : 339 - 345
  • [50] Non-invasive decision support for clinical treatment of non-small cell lung cancer using a multiscale radiomics approach
    Zhang, Xingping
    Zhang, Guijuan
    Qiu, Xingting
    Yin, Jiao
    Tan, Wenjun
    Yin, Xiaoxia
    Yang, Hong
    Wang, Hua
    Zhang, Yanchun
    RADIOTHERAPY AND ONCOLOGY, 2024, 191